ATI RN
ATI Proctored Pharmacology Test
1. When administering digoxin (Lanoxin) to a patient, the healthcare provider observes various signs and symptoms of an overdose. Which of the following should the healthcare provider give to reverse digoxin toxicity?
- A. Naloxone
- B. Vitamin K
- C. Digibind
- D. Flumazenil
Correct answer: C
Rationale: Digibind, also known as Digoxin immune Fab, is the specific antidote used to treat digoxin toxicity. It works by binding to digoxin in the body, forming a complex that can be excreted by the kidneys, thereby reversing the toxic effects of digoxin overdose. Naloxone is used for opioid overdoses, not digoxin toxicity. Vitamin K is used to reverse the effects of warfarin overdose. Flumazenil is used to reverse the effects of benzodiazepine overdose, not digoxin toxicity.
2. A healthcare provider is planning to administer IV Alteplase to a client who is demonstrating manifestations of a massive Pulmonary Embolism. Which of the following interventions should the healthcare provider plan to take?
- A. Administer IM Enoxaparin along with the Alteplase dose.
- B. Hold direct pressure on puncture sites for up to 30 minutes.
- C. Administer Aminocaproic acid IV prior to alteplase infusion.
- D. Prepare to administer Alteplase within 8 hours of manifestation onset.
Correct answer: B
Rationale: When administering IV Alteplase for a massive Pulmonary Embolism, the healthcare provider should plan to hold direct pressure on puncture sites for 10 to 30 minutes or until oozing of blood stops. This is crucial to prevent bleeding complications at the puncture sites. Choice A is incorrect because Enoxaparin is not usually administered along with Alteplase for a Pulmonary Embolism. Choice C is incorrect because Aminocaproic acid is not typically given prior to alteplase infusion in this situation. Choice D is incorrect because Alteplase should be administered within 2 hours of onset of manifestations for Pulmonary Embolism, not within 8 hours.
3. What is an expected outcome for Lithium use in patients with bipolar disorder?
- A. Reduced risk of myocardial infarction
- B. Reduced risk of GI ulcers
- C. Decrease in respiratory distress
- D. Decreased incidence of acute manic episodes
Correct answer: D
Rationale: The correct answer is D: Decreased incidence of acute manic episodes. Lithium is commonly used to treat bipolar disorder by helping to stabilize mood and reduce the intensity and frequency of manic episodes. This leads to better overall management of the disorder. Choices A, B, and C are incorrect because lithium is not known to reduce the risk of myocardial infarction, GI ulcers, or respiratory distress in patients with bipolar disorder.
4. A client has a prescription for ceftriaxone. Which of the following information should the nurse include in the teaching?
- A. You may develop a cough while taking this medication.
- B. You should stop taking this medication if you develop a rash.
- C. This medication cannot be given orally.
- D. This medication may cause your urine to turn yellow.
Correct answer: B
Rationale: The correct answer is B. A rash can indicate an allergic reaction to ceftriaxone, which should be reported to the provider. It is crucial to instruct the client to discontinue the medication and seek medical attention if a rash develops to prevent potential serious adverse effects. Choices A, C, and D are incorrect because cough is not a common side effect of ceftriaxone, ceftriaxone is typically administered parenterally, and a yellow discoloration of urine is a harmless side effect due to the color of the medication itself, respectively.
5. A client has a new prescription for Hydrochlorothiazide. Which of the following adverse effects should the nurse monitor?
- A. Hyponatremia
- B. Hyperkalemia
- C. Hypercalcemia
- D. Hypoglycemia
Correct answer: A
Rationale: Corrected Rationale: Hydrochlorothiazide is a diuretic known to cause electrolyte imbalances, particularly hyponatremia (low sodium levels). The nurse should closely monitor the client for signs of hyponatremia by assessing their electrolyte levels. Choice B, Hyperkalemia, is incorrect as hydrochlorothiazide is more likely to cause hypokalemia (low potassium levels) rather than hyperkalemia. Choice C, Hypercalcemia, is incorrect because hydrochlorothiazide is not known to cause increased calcium levels. Choice D, Hypoglycemia, is also incorrect as it is not a common adverse effect of hydrochlorothiazide.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access